DADC
AST

D.A. Davidson & Co’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

D.A. Davidson & Co’s Portfolio AST Stock Details AST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-4
Closed – – 2386
2017
Q2 		$0 Hold
4
– – ﹤0.01% 2519
2017
Q1 		$0 Buy
+4
New +$16 ﹤0.01% 2618

Other funds holding AST

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

D.A. Davidson & Co's AST Position: Q3 2017 in Review

D.A. Davidson & Co sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q3 2017, closing a stake of 4 shares.

D.A. Davidson & Co first reported a position in AST in Q1 2017 and held it in 2 quarters. The position peaked at $0 in Q2 2017. 62 funds tracked by Wall St. Rank hold AST as of Q3 2017.

  • D.A. Davidson & Co reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q3 2017 after selling out during the quarter.
  • D.A. Davidson & Co sold 4 Asterias Biotherapeutics Inc. Series A shares in Q3 2017.
  • D.A. Davidson & Co first reported a position in Asterias Biotherapeutics Inc. Series A in Q1 2017 and held it in 2 quarters.
  • D.A. Davidson & Co's Asterias Biotherapeutics Inc. Series A position peaked at $0 in Q2 2017.
  • 62 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q3 2017.

Based on D.A. Davidson & Co's 13F filing for Q3 2017, filed 8 Nov 2017.